Suppr超能文献

基质 PD-L1 和肿瘤核 β-连环蛋白表达的联合作为局部晚期直肠癌进展和对放化疗耐药的标志物。

A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.

机构信息

Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.

Department of Pathology, Kitasato University School of Allied Health Science, Sagamihara, Japan.

出版信息

J Pathol Clin Res. 2022 Sep;8(5):458-469. doi: 10.1002/cjp2.285. Epub 2022 Jun 27.

Abstract

Programmed cell death-1 (PD-1) and its ligand (PD-L1) are significant mediators of immune suppression in the tumor microenvironment. We focused on the immunological impact of PD-1/PD-L1 signaling during tumor progression in colorectal carcinoma (CRC) and its association with resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal carcinoma (LAd-RC). Histopathological and immunohistochemical analyses of 100 CRC cases (including 34 RC) without NCRT and 109 NCRT-treated LAd-RC cases were performed. Membranous tumoral PD-L1 expression was identified in 9 of 100 (9%) CRC cases, including 1 of 34 (2.9%) RC cases, but PD-L1 immunopositivity was not associated with any clinicopathological factors, with the exception of deficient mismatch repair (dMMR) status. In contrast, stromal PD-L1+ immune cells, which frequently exhibited coexpression of PD-1 and CD8 markers, were significantly correlated with tumor vessel invasion, nuclear β-catenin+ tumor budding cancer stem cell (CSC)-like features, and unfavorable prognosis. In the LAd-RC cases, stromal CD8+ (but not PD-L1+) immune cell infiltration in pretreatment-biopsied samples was significantly and positively associated with therapeutic efficacy. After NCRT, tumoral PD-L1 expression was observed in only 2 of 83 (2.4%) tumors, independent of dMMR status, whereas high stromal PD-L1+ and tumoral nuclear β-catenin positivity were significantly linked to a poor response to NCRT and high tumor budding features. In addition, high stromal PD-L1 immunoreactivity was significantly associated with poorer overall survival. In conclusion, a combination of stromal PD-L1+ immune cells and nuclear β-catenin+ tumor budding may contribute to tumor progression in CRC and resistance to NCRT in LAd-RC, through formation of niche-like lesions that exhibit immune resistance and CSC properties.

摘要

程序性细胞死亡受体 1(PD-1)及其配体(PD-L1)是肿瘤微环境中免疫抑制的重要介质。我们专注于 PD-1/PD-L1 信号在结直肠癌(CRC)肿瘤进展过程中的免疫学影响及其与局部晚期直肠腺癌(LAd-RC)新辅助放化疗(NCRT)抵抗的关系。对 100 例未经 NCRT 的 CRC 病例(包括 34 例 RC)和 109 例接受 NCRT 的 LAd-RC 病例进行了组织病理学和免疫组织化学分析。在 100 例 CRC 病例(包括 34 例 RC)中,有 9 例(9%)肿瘤存在膜性肿瘤 PD-L1 表达,其中 1 例(2.9%)RC 病例存在 PD-L1 免疫阳性,但 PD-L1 免疫阳性与除错配修复缺陷(dMMR)状态以外的任何临床病理因素均无关。相反,基质 PD-L1+免疫细胞常与 PD-1 和 CD8 标志物共表达,与肿瘤血管浸润、核β-连环蛋白+肿瘤芽肿瘤干细胞(CSC)样特征以及不良预后显著相关。在 LAd-RC 病例中,预处理活检样本中基质 CD8+(而非 PD-L1+)免疫细胞浸润与治疗效果显著正相关。NCRT 后,仅在 83 例肿瘤中的 2 例(2.4%)中观察到肿瘤 PD-L1 表达,与 dMMR 状态无关,而高基质 PD-L1+和肿瘤核β-连环蛋白阳性与 NCRT 反应不良和高肿瘤芽特征显著相关。此外,高基质 PD-L1 免疫反应性与总生存期较差显著相关。总之,基质 PD-L1+免疫细胞和核β-连环蛋白+肿瘤芽的结合可能通过形成具有免疫抵抗和 CSC 特性的类似龛位样病变,促进 CRC 肿瘤的进展和 LAd-RC 对 NCRT 的抵抗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a501/9353658/61ff20725872/CJP2-8-458-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验